Microbiological Conclusions

Overview

Journal Drugs

Specialty Pharmacology

Date 1991 Jan 1

PMID 1726204

Authors

R N Jones

Affiliations

Soon will be listed here.

References

Fujii R . Clinical trials of cefpodoxime proxetil suspension in paediatrics. Drugs. 1991; 42 Suppl 3:57-60. DOI: 10.2165/00003495-199100423-00011. View

Jones R, Barry A . Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Antimicrob Agents Chemother. 1988; 32(4):443-9. PMC: 172198. DOI: 10.1128/AAC.32.4.443. View

Wiedemann B, Luhmer E, Zuhlsdorf M . Microbiological evaluation of cefpodoxime proxetil. Drugs. 1991; 42 Suppl 3:6-12. DOI: 10.2165/00003495-199100423-00004. View

Utsui Y, Inoue M, Mitsuhashi S . In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrob Agents Chemother. 1987; 31(7):1085-92. PMC: 174876. DOI: 10.1128/AAC.31.7.1085. View

Jones R, Barry A, Pfaller M, Allen S, Ayers L, Fuchs P . Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control. Diagn Microbiol Infect Dis. 1988; 9(1):59-63. DOI: 10.1016/0732-8893(88)90063-6. View